Toulouse University Hospital
🇫🇷France
Lixisenatide Shows Promise in Slowing Parkinson's Disease Progression in Phase 2 Trial
A Phase 2 trial of Sanofi's lixisenatide demonstrated the GLP-1 agonist's potential to halt motor symptom progression in Parkinson's disease patients over 12 months.